Literature DB >> 4064469

A simple method for the estimation of glomerular filtration rate by gentamicin pharmacokinetics during routine drug monitoring in the newborn.

G Koren, A James, M Perlman.   

Abstract

Assessment of the glomerular filtration rate (GFR) in the newborn is often imprecise because of difficulties in urine collection and because the plasma creatinine level, the traditional marker of renal function, is influenced by many factors in this age group. Gentamicin is given to most preterm infants for suspected or proved sepsis. This drug is eliminated almost entirely by the kidney and its rate of elimination parallels the GFR. We calculated gentamicin pharmacokinetic parameters (t1/2, volume of distribution, and clearance) from three consecutive concentration-time points (trough, peak, and next trough levels) in 38 newborn infants. Creatinine clearance was measured by the conventional method. Both t1/2 (r = 0.74; P less than 0.001) and gentamicin clearance (r = 0.77; P less than 0.001) correlated well with measured creatinine clearance. There was no correlation between these variables and urine output. Gentamicin elimination t1/2 and clearance are useful indices of GFR in the newborn infant and can be easily calculated during routine therapeutic drug monitoring.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4064469     DOI: 10.1038/clpt.1985.245

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  24 in total

1.  Amikacin maturation model as a marker of renal maturation to predict glomerular filtration rate and vancomycin clearance in neonates.

Authors:  Wei Zhao; Valérie Biran; Evelyne Jacqz-Aigrain
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

2.  The impact of ibuprofen on renal clearance in preterm infants is independent of the gestational age.

Authors:  Karel Allegaert; Veerle Cossey; Anne Debeer; Jean Paul Langhendries; Bart Van Overmeire; Jan de Hoon; Hugo Devlieger
Journal:  Pediatr Nephrol       Date:  2005-03-23       Impact factor: 3.714

3.  Limited predictability of amikacin clearance in extreme premature neonates at birth.

Authors:  Karel Allegaert; Brian J Anderson; Veerle Cossey; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

4.  Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis.

Authors:  Catherine M T Sherwin; Sofia Svahn; Antje Van der Linden; Roland S Broadbent; Natalie J Medlicott; David M Reith
Journal:  Eur J Clin Pharmacol       Date:  2009-03-21       Impact factor: 2.953

Review 5.  Clinical pharmacology of the perinatal period and early infancy.

Authors:  P L Morselli
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

6.  Optimum Use of Therapeutic Drug Monitoring and Pharmacokinetics-Pharmacodynamics in the NICU.

Authors:  Peter Gal
Journal:  J Pediatr Pharmacol Ther       Date:  2009-04

7.  Nonselective cyclo-oxygenase inhibitors and glomerular filtration rate in preterm neonates.

Authors:  Karel Allegaert; Christine Vanhole; Jan de Hoon; Jean Pierre Guignard; Dick Tibboel; Hugo Devlieger; Bart Van Overmeire
Journal:  Pediatr Nephrol       Date:  2005-08-16       Impact factor: 3.714

Review 8.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  Impact of gestational age and birth weight on amikacin clearance on day 1 of life.

Authors:  Michiel F Schreuder; Abraham J Wilhelm; Arend Bökenkamp; Simone M H Timmermans; Henriette A Delemarre-van de Waal; Joanna A E van Wijk
Journal:  Clin J Am Soc Nephrol       Date:  2009-08-27       Impact factor: 8.237

10.  Gentamicin interval in newborn infants as determined by renal function and postconceptional age.

Authors:  L P Brion; A R Fleischman; G J Schwartz
Journal:  Pediatr Nephrol       Date:  1991-11       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.